TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18447091
Drug: Breathing Awareness
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing Awareness Meditation (BAM), 10-minute sessions daily for three months
Study: 14579656
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) nasal spray for 2 weeks
Study: 14579656
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (DMM) nasal spray
Study: 9686728
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin treatment for Ureaplasma urealyticum colonized infants.
Study: 21323911
Drug: Cockroach immunotherapy
Normalized name: American cockroach allergenic extract
DrugBank: Periplaneta americana (DB10417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockroach immunotherapy (IT) with Periplaneta americana extract
Study: 23417481
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg)
Study: 8826606
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus G‐CSF (5 micrograms/kg/day, s.c.)
Study: 8826606
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (ceftazidime, 2 g, i.v., every 8 h + amikacin 7.5 mg/kg, i.v., every 12 h)
Study: 1421390
Drug: rhuGM‐CSF 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuGM‐CSF 250 micrograms/m2 daily by continuous infusion after ABMT
Study: 25719344
Drug: Ginger (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (3 g powdered ginger daily for 3 months)
Study: 25719344
Drug: Placebo (lactose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose, daily for 3 months)
Study: 15895715
Drug: rhASB 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhASB 1.0 mg/kg/week
Study: 15895715
Drug: rhASB 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhASB 0.2 mg/kg/week
Study: 15895715
Drug: rhASB (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhASB (both doses)
Study: 9392980
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg intramuscular triamcinolone acetonide
Study: 7699233
Drug: Lactitol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol 0.3 g/kg bw per day
Study: 7699233
Drug: Lactitol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol 0.5 g/kg bw per day
Study: 30479286
Drug: Half-dose MBI
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose MBI (150 MBq Tc-99m sestamibi; images acquired for 10 minutes per view)
Study: 30479286
Drug: Half-dose or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose or half-time MBI
Study: 23287785
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator
Study: 21633719
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol combination (FSC) 100/50 mcg BID
Study: 18951261
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 mcg BID
Study: 16526203
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of micronized fenofibrate
Study: 30199512
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections
Study: 7709266
Drug: Narcotic analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic analgesics
Study: 1790087
Drug: Magaldrate (MAG)
Normalized name: Magaldrate
DrugBank: Magaldrate (DB08938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate (MAG) 800 mg bid
Study: 1790087
Drug: Aceglutamide aluminium
Normalized name: aceglutamide aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceglutamide aluminium salt (AAL) 700 mg bid
Study: 6166245
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (5 to 7 days therapy)
Study: 20579524
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (0.5 L/d) containing eicosapentaenoic acid, docosahexaenoic acid, oleic acid, vitamins A, B(6), E, and folic acid
Study: 20579524
Drug: Semiskimmed milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiskimmed milk (0.5 L/d)
Study: 16478764
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg) with metformin
Study: 16478764
Drug: Clomiphene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (100 mg) with metformin
Study: 3889759
Drug: 5-FU alone
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU alone (15 mg/kg)
Study: 24880449
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate (875/125mg)
Study: 24880449
Drug: Amoxicillin (1g)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (1g)
Study: 20430912
Drug: Osteopathy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathy in the cranial field (treatment group)
Study: 15811060
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction and professional tooth cleaning
Study: 8819807
Drug: Holter monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Holter monitoring (HM) for 24 hours during common everyday activities and after suspending anti-ischemic therapy
Study: 1758528
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) administered subcutaneously
Study: 25434645
Drug: Chlorhexidine (CHD)
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHD) spray on umbilical cord three times a day for three days after cord fall
Study: 24266715
Drug: Rosiglitazone 4-8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4-8 mg
Study: 22116543
Drug: Ponstan® capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponstan® capsule (250 mg)
Study: 22116543
Drug: Mephenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mephenamic acid microspheres (250 mg)
Study: 15805229
Drug: Somatostatin-heparin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-heparin infusion (suppressed insulin, high FFA)
Study: 9310023
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 micrograms b.i.d. via diskhaler)
Study: 2882289
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine (MMU‐18006) - 10^4 plaque-forming units, orally administered
Study: 28078540
Drug: Capecitabine 2500
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2500 mg/m2/day for 12 months (16 cycles)
Study: 28078540
Drug: Capecitabine 2500
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2500 mg/m2/day for 6 months (8 cycles)
Study: 25143556
Drug: Paricalcitol (PCT)
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol (PCT) 1 μg/day for 6 months
Study: 21660675
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine for calming Gan and suppressing hyperactive yang (CGSHY)
Study: 19186717
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Clomiphene and intramuscular injection of Chorionic Gonadotropin
Study: 8344096
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment (combined data)
Study: 19187557
Drug: Aquamin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquamin (2400 mg/d)
Study: 18279523
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg/d)
Study: 12749506
Drug: Diclofenac-K 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac-K 12.5 mg
Study: 10863250
Drug: Behavioral-graded activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral-graded activity program based on operant therapy
Study: 2493869
Drug: Sodium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium supplementation (Slow Sodium 80 mmol daily) for one month
Study: 19122550
Drug: Landiolol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (bolus injection of 0.031 mg.kg(‐1) and continuous infusion at a rate of 0.01 mg.kg(‐1).min(‐1))
Study: 2289489
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg)
Study: 15447905
Drug: Dual-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-fortified salt (DFS) with 25 microg I/g salt and 2 mg Fe/g salt
Study: 9541184
Drug: High risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk patients with positive hormone receptors
Study: 8772223
Drug: Synthetic pentasaccharide
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic pentasaccharide (SR 90107/ORG 31540) administered subcutaneously at doses of 4000, 8000, or 12,000 anti-Xa units (6, 12, or 18 mg)
Study: 23979731
Drug: AIGIV (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIGIV (3.5 mg/kg)
Study: 23979731
Drug: AIGIV (7.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIGIV (7.1 mg/kg)
Study: 23979731
Drug: AIGIV (14.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIGIV (14.2 mg/kg)
Study: 23979731
Drug: AIGIV administered
Normalized name: IGIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIGIV administered 12 h postexposure
Study: 23979731
Drug: AIGIV administered
Normalized name: IGIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIGIV administered 24 h postexposure
Study: 17284637
Drug: EP01572 (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP01572 (0.125 and 0.25 mg/kg body weight)
Study: 17284637
Drug: ID administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID administration of EP01572 (0.2 mg/kg body weight)
Study: 15123848
Drug: Lithium or
Normalized name: Lithium Orotate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium or desipramine augmentation
Study: 11310719
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg capsule
Study: 3054197
Drug: 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/kg of Bpr combined with local anesthetic (group B)
Study: 3054197
Drug: 2 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mcg/kg of Bpr combined with local anesthetic (group C)
Study: 11502644
Drug: Tezosentan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (50 mg/h)
Study: 12535809
Drug: Tezosentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (100 mg/h)
Study: 3937970
Drug: Therapy A
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy A (vincristine/ifosfamide/tegafur)
Study: 30915778
Drug: Diet +
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet + myo-inositol (MI) 4 g + folic acid 400 µg daily (Group 2, n = 10)
Study: 26265098
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg administered every 12 hours for 4.5 days
Study: 20352415
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg modafinil
Study: 7865087
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I - oral hygiene training program based on self-diagnosis and the 'linking method'; 20 minutes sessions at two-day intervals for the first three visits, followed by monthly check-ups for 4 months and then every 3 months for reevaluation.
Study: 7865087
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II - detailed oral hygiene instruction on cleaning every tooth surface using dental tape, toothbrush, and fluoride dentifrice; same recall intervals as Group I.
Study: 30192329
Drug: Intraperitoneal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal local anesthetic (ropivacaine 100 mg bolus pre- and post-dissection, 20 mg/h continuous infusion for 48 hours)
Study: 27435972
Drug: Naloxegol 12.5
Normalized name: naloxegol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 12.5 mg/day
Study: 27435972
Drug: Naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 25 mg/day
Study: 18362865
Drug: UC781 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC781 gel 1%
Study: 18362865
Drug: UC781 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC781 gel (all concentrations)
Study: 11079860
Drug: PTEVAL computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTEVAL computerized home-based physical therapy intervention
Study: 1524994
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with monitoring of white blood cell counts (WBC) and absolute neutrophil counts (ANC)
Study: 1524994
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with monitoring of WBC and ANC
Study: 3888726
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ibuprofen/kg body-weight
Study: 18593651
Drug: Single vital-capacity
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vital-capacity breathing with 7.2% inspiratory sevoflurane in 6 L/min oxygen followed by assisted ventilation with 3.5% sevoflurane for 4.5 minutes.
Study: 16442890
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) combined with optimal medical treatment
Study: 23922146
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment alone
Study: 14617231
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily BIAsp30
Study: 14617231
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily NPH insulin
Study: 1364936
Drug: Enteric-coated naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated naproxen tablets (ECT)
Study: 31464476
Drug: Oral exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exogenous progesterone (200 mg twice per day)
Study: 28747330
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein load of 30 g (120 kcal)
Study: 28747330
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein load of 70 g (280 kcal)
Study: 28747330
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (both doses)
Study: 18353696
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (0.6 mg, 25 microg/h)
Study: 18353696
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (15 mg)
Study: 11505794
Drug: Cannula injection
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannula injection of somatropin (8.64 IU)
Study: 7682088
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (12 g/m2)
Study: 7682088
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (6 g/m2)
Study: 7682088
Drug: Alternative postsurgical
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative postsurgical chemotherapy for poor responders
Study: 3803252
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg every 8 hours for 10 days
Study: 24886064
Drug: Tenecteplase 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.4 mg/kg (single bolus)
Study: 24886064
Drug: Alteplase 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)
Study: 8869018
Drug: Abciximab (c7E3)
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab (c7E3) administered at the time of angioplasty or directional coronary atherectomy
Study: 7467371
Drug: Isoket-spray (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoket-spray (3.75 mg)
Study: 7467371
Drug: Placebo-spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-spray
Study: 30875097
Drug: NSS powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSS powder (1 g/day)
Study: 10451461
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Vitamin D and Calcium)
Study: 2141491
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol Acetate (MA) 2 X 80 mg p.o. daily
Study: 19690349
Drug: AZD0837 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 (150, 300, 450 mg once daily or 200 mg twice daily)
Study: 16456412
Drug: Nominal starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nominal starting dose of PEG 4000
Study: 16456412
Drug: Double starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Double starting dose of PEG 4000
Study: 16456412
Drug: PEG 4000
Normalized name: PEG 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 4000 treatment
Study: 17920256
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg daily
Study: 17136986
Drug: Tiotropium 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 36 mcg daily
Study: 10404354
Drug: Losartan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12.5 mg, titrated to 50 mg once daily)
Study: 7013510
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin solution
Study: 29044915
Drug: Pre-discharge troponin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-discharge troponin elevation (>0.04 ng/mL)
Study: 29044915
Drug: 1-month troponin
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month troponin elevation (>0.04 ng/mL)
Study: 28433366
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol)
Study: 30478024
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy
Study: 8844228
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1.5 mg/kg per h continuously for 5 days after a loading dose of 600 mg
Study: 15385341
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control)
Study: 22845895
Drug: bup100 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bup100 (300 mg)
Study: 22845895
Drug: pla (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pla (200 mg)
Study: 22845895
Drug: bup50 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bup50 (150 mg) and bup75 (225 mg)
Study: 19931549
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cortisol (administered in a double-blind, placebo-controlled crossover design)
Study: 18817234
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mL of 2% lidocaine and 0.9% saline)
Study: 16274097
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day for 4 months
Study: 7868909
Drug: IL‐1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1 and IL‐1 receptor antagonist (IL‐1ra) production in IBD patients
Study: 27659126
Drug: High-protein meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meals during dialysis (50-55 g) combined with lanthanum carbonate
Study: 19741312
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise (1 hour twice a week for 12 months)
Study: 343968
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fendosal
Study: 1544291
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg aspirin
Study: 343968
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg fendosal
Study: 18398475
Drug: PfCP‐2.9 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfCP‐2.9 vaccine (20, 50, 100, or 200 microg)